Dr. Thomas Boland
Dr. Thomas Boland, Chief Science Advisor and co-founder of TeVido BioDevices currently holds, in association with Clemson University, a US Patent with broad claims for inkjet tissue printing. Live-cell tissue printing has been his primary field of research for over 10 years, and he has received over $8M in research funding for his work. Dr. Boland’s work has been cited more than 800 times. He’s received numerous awards and was featured on CNN and the Discovery Channel for his groundbreaking research using inkjet printers to assemble cells and biomaterials into viable and functioning structures. Dr Boland is the Director of Biomedical Engineering at the University of Texas at El Paso (UTEP).
Dr. Frank Agullo
Francisco Agullo, M.D., is certified by the American Board of Plastic Surgery and the American Board of Surgery. He has joined El Paso Cosmetic Surgery as a plastic surgeon serving the cosmetic needs of West Texas, New Mexico, and Northern Mexico.
Dr. Frank Agullo graduated from the world-famous Mayo Clinic in Rochester, Minnesota, and he stays current in all of the latest aesthetic procedures and technologies. Dr. Agullo also holds the position of clinical assistant professor at Texas Tech University.
Jana Stoudemire is a vice president in Porter Novelli’s Austin office and brings extensive healthcare and life science experience to the team. She has worked in the biotechnology, pharmaceutical and medical device industries for the last 18+ years and has a strong understanding of the needs and challenges faced by companies working within a regulated industry. She has experience working in both emerging and established global markets spanning a variety of indications.
Prior to joining Porter Novelli projects, Jana has worked on include development of neurogenic drugs to treat mood disorders, PTSD, Parkinson’s and other CNS diseases, use of supercritical fluid technology to create drug-eluting coatings for cardiovascular coronary and peripheral stents, orthopedic, and drug-delivery devices, and development of recombinant human growth hormones. She also led the team that successfully commercialized the first FDA approved human tissue-engineered skin products for burns and diabetic foot ulcers. In addition to her strong technical background, her expertise includes government affairs, investor relations, and corporate communications strategy.
Elisa Maldonado-Holmertz has over 20 years experience in multinational pharma, life sciences and medical device industries. She has worked locally in both emerging and established markets (USA, Belgium, Sweden, P.R. China) spanning an array of indications including wound healing. Most relevant to TeVido, she has been integral to several start-ups. In addition to her industry background, she has graduate work in Business Management and Health Economics. Her experience in clinical research, reimbursement and market access, marketing and sales, and RA/QA are of tremendous value to TeVido. Ms. Maldonado-Holmertz has recently left her position as VP Business Development at Emergo Group to pursue consulting.